| 21.29 2.95 (16.09%) | 04-20 13:35 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.8  |
1-year : | 33.64 |
| Resists | First : | 24.65 |
Second : | 28.8 |
| Pivot price | 15.94 |
|||
| Supports | First : | 17.31 |
Second : | 12.77 |
| MAs | MA(5) : | 18.13 |
MA(20) : | 15.33 |
| MA(100) : | 15.03 |
MA(250) : | 13.85 |
|
| MACD | MACD : | 1 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 84.1 |
D(3) : | 90.5 |
| RSI | RSI(14): 80.1 |
|||
| 52-week | High : | 24.65 | Low : | 8.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GHRS ] has closed It is unclear right now based on current values. 143.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 18.71 - 18.77 | 18.77 - 18.83 |
| Low: | 17.48 - 17.54 | 17.54 - 17.62 |
| Close: | 18.22 - 18.32 | 18.32 - 18.44 |
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Mon, 20 Apr 2026
GH Research: WH Decision On Psychedelics To Treat Depression Makes Bull Case (NASDAQ:GHRS) - Seeking Alpha
Mon, 20 Apr 2026
GH Research stock hits 52-week high at $21.44 By Investing.com - Investing.com Canada
Mon, 20 Apr 2026
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness - GlobeNewswire
Mon, 20 Apr 2026
White House mental illness order aligns with GH Research's 2026 Phase 3 plan - Stock Titan
Sat, 18 Apr 2026
Florian Schonharting Net Worth (2026) - GuruFocus
Fri, 17 Apr 2026
Duncan Moore of GH Research (NASDAQ: GHRS) reports shares and vested options - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 26.7 (%) |
| Held by Institutions | 74.9 (%) |
| Shares Short | 2,210 (K) |
| Shares Short P.Month | 2,700 (K) |
| EPS | -0.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.51 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -16 % |
| Return on Equity (ttm) | -21.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -26.4 |
| PEG Ratio | 0 |
| Price to Book value | 4.62 |
| Price to Sales | 0 |
| Price to Cash Flow | -29.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|